Új vizsgálatok, publikációk, preprintek és pályázatok ezen a célponton, hónapról hónapra.
Vizsgálat
IDH1-vac in Patients With Newly Diagnosed IDH1R132H-positive High-grade Astrocytomas
2027. febr. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)
2026. nov. 27.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publikáció
Frequent FLT3 and IDH co-mutations in acute myeloid leukemia with mutated NPM1, NUP98 rearrangement, and KMT2A partial tandem duplication but not rearrangement: potential for combined targeted therapy.
2026. nov. 5.· Haematologica· PUBMED
Publikáció
Distinct clinical and molecular profiles of acute myeloid leukemia defined by mutations in IDH1, IDH2, and TET2.
2026. nov. 5.· Haematologica· PUBMED
Publikáció
Measurable Residual Disease in IDH-Mutated AML: Identifying a Clinically Relevant Threshold for IDH Mutation Monitoring.
2026. nov. 2.· European journal of haematology· PUBMED
Vizsgálat
Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax
2026. nov. 1.· PHASE2 · RECRUITING· CTGOV
Publikáció
Deep learning predicts IDH1 mutation status in acute myeloid leukemia from bone marrow smears.
2026. okt. 29.· NPJ precision oncology· PUBMED
Publikáció
IDH2 p.R172 mutation Predicts Superior Outcomes in IDH-mutated Acute Myeloid Leukemia or Myelodysplastic Syndrome patients undergoing Allogeneic Hematopoietic Cell Transplantation: a retrospective study from the Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH-TC).
2026. okt. 28.· Transplantation and cellular therapy· PUBMED
Publikáció
Contrasting molecular and pharmacodynamic signatures of response and resistance to sequential bortezomib and temozolomide in recurrent IDH-wildtype glioblastoma and grade 4 IDH-mutant astrocytoma: an exploratory interim analysis of NCT03643549 phase IB/II trial.
2026. okt. 27.· Biomarker research· PUBMED
Publikáció
Dynamics of IDH1 Mutation and Protein Expression Between Primary and Recurrent Gliomas and Their Prognostic Significance.
2026. okt. 27.· Human mutation· PUBMED
Publikáció
Therapy-related T-lymphoblastic lymphoma following acute myeloid leukemia remission with IDH2 mutation persistence.
2026. okt. 16.· Leukemia research reports· PUBMED
Publikáció
A spectrum of tumorigenesis in an IDH1-mosaic patient with Ollier disease, acute myeloid leukaemia, and parathyroid adenoma.
2026. okt. 9.· Frontiers in genetics· PUBMED
Publikáció
Genome-wide CRISPR screen identifies PKMYT1 inhibition as a synthetic lethal vulnerability in IDH1-mutant glioma.
2026. okt. 8.· Cancer letters· PUBMED
Publikáció
[18F]FET uptake in diffuse lower-grade IDH-mutant glioma correlates with glioma-related epilepsy.
2026. okt. 1.· Journal of neuro-oncology· PUBMED
Publikáció
Molecularly Guided Therapy and the Tumor Microenvironment in Advanced Cholangiocarcinoma: Current Evidence and Emerging Strategies Targeting FGFR2, HER2, and IDH1 with Pemigatinib, Zanidatamab, and Ivosidenib.
2026. szept. 23.· Journal of clinical medicine· PUBMED
Publikáció
Autophagy inhibition sensitizes radiotherapy responses in high-grade mutant IDH1 glioma.
2026. szept. 18.· Nature communications· PUBMED
Publikáció
Murine modeling of IDH-mutant 1p/19q-codeleted oligodendroglioma reveals genotype specific phenotypes.
2026. szept. 17.· Neuro-oncology· PUBMED
Publikáció
Exploration of Bacopa monnieri-derived Green Ligands for Targeted IDH1 Inhibition in Glioblastoma.
2026. szept. 16.· Current drug discovery technologies· PUBMED
Publikáció
Spatial analysis reveals the evolving organization of IDH-mutant glioma.
2026. szept. 14.· Cancer cell· PUBMED
Publikáció
APOBEC3 activity and DNA polymerase-ε deficiency are associated with distinct IDH1 R132 hotspot mutations.
2026. szept. 9.· Molecular oncology· PUBMED
Publikáció
Diffusion histogram analysis predicts progression-free survival in contrast enhancing recurrent IDH mutant gliomas treated with bevacizumab.
2026. szept. 9.· Journal of neuro-oncology· PUBMED
Publikáció
Histopathologic, Genomic, and Clinical Characteristics of Primary Cutaneous Melanocytic Tumors With Concomitant NRAS Q61 and IDH1 R132C Mutations.
2026. szept. 8.· Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc· PUBMED
Publikáció
LY3410738, a Covalent Inhibitor of Mutant IDH1/2, Is Effective in Acute Myeloid Leukemia Preclinical Models.
2026. szept. 3.· Blood cancer discovery· PUBMED
Publikáció
Real-world experience with IDH inhibitors in pediatric patients with IDH1- and IDH2-mutated acute myeloid leukemia and myelodysplastic syndrome.
2026. szept. 3.· Haematologica· PUBMED
Publikáció
Metabolomic and lipidomic profiling reveals distinct subtypes of glioblastoma IDH-wildtype and shared metabolic features with astrocytoma IDH-mutant grade 4.
2026. szept. 2.· Neuro-oncology advances· PUBMED
Vizsgálat
Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy.
2026. szept. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publikáció
cIMPACT-NOW Update 12: Refining pathology-based risk stratification and grading for IDH-mutant gliomas.
2026. szept. 1.· Neuro-oncology· PUBMED
Publikáció
Targeting IDH-driven Oncometabolism in glioblastoma: a computational approach for the identification of potential inhibitors.
2026. aug. 26.· Frontiers in bioinformatics· PUBMED
Publikáció
The PRIME trial: An investigator-initiated, multicentre, phase II study of the poly(ADP-ribose) polymerase inhibitor olaparib in isocitrate dehydrogenase (IDH)-mutated relapsed/refractory acute myeloid leukaemia and myelodysplastic syndromes.
2026. aug. 26.· British journal of haematology· PUBMED
Publikáció
Ivosidenib monotherapy in IDH1 mutated myelodysplastic neoplasm/syndrome.
2026. aug. 25.· Leukemia· PUBMED